0000905148-21-000408.txt : 20210429
0000905148-21-000408.hdr.sgml : 20210429
20210429184407
ACCESSION NUMBER: 0000905148-21-000408
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20210427
FILED AS OF DATE: 20210429
DATE AS OF CHANGE: 20210429
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: GOODMAN COREY S
CENTRAL INDEX KEY: 0001278411
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-40353
FILM NUMBER: 21872810
MAIL ADDRESS:
STREET 1: 1700 OWENS STREET
STREET 2: SUITE 595
CITY: SAN FRANCISCO
STATE: CA
ZIP: 94158
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Adelman Robert J
CENTRAL INDEX KEY: 0001329161
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-40353
FILM NUMBER: 21872809
MAIL ADDRESS:
STREET 1: 1700 OWENS STREET
STREET 2: SUITE 595
CITY: SAN FRANCISCO
STATE: CA
ZIP: 94158
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: venBio Global Strategic GP II, L.P.
CENTRAL INDEX KEY: 0001729409
STATE OF INCORPORATION: E9
FISCAL YEAR END: 1231
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-40353
FILM NUMBER: 21872812
BUSINESS ADDRESS:
STREET 1: 1700 OWENS STREET
STREET 2: SUITE 595
CITY: SAN FRANCISCO
STATE: CA
ZIP: 94158
BUSINESS PHONE: 415-522-0100
MAIL ADDRESS:
STREET 1: 1700 OWENS STREET
STREET 2: SUITE 595
CITY: SAN FRANCISCO
STATE: CA
ZIP: 94158
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: venBio Global Strategic Fund II L.P.
CENTRAL INDEX KEY: 0001634632
STATE OF INCORPORATION: E9
FISCAL YEAR END: 1231
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-40353
FILM NUMBER: 21872813
BUSINESS ADDRESS:
STREET 1: 1700 OWENS STREET
STREET 2: SUITE 595
CITY: SAN FRANCISCO
STATE: CA
ZIP: 94158
BUSINESS PHONE: 415-522-0100
MAIL ADDRESS:
STREET 1: 1700 OWENS STREET
STREET 2: SUITE 595
CITY: SAN FRANCISCO
STATE: CA
ZIP: 94158
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: venBio Global Strategic GP II, Ltd.
CENTRAL INDEX KEY: 0001729408
STATE OF INCORPORATION: E9
FISCAL YEAR END: 1231
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-40353
FILM NUMBER: 21872811
BUSINESS ADDRESS:
STREET 1: 1700 OWENS STREET
STREET 2: SUITE 595
CITY: SAN FRANCISCO
STATE: CA
ZIP: 94158
BUSINESS PHONE: 415-522-0100
MAIL ADDRESS:
STREET 1: 1700 OWENS STREET
STREET 2: SUITE 595
CITY: SAN FRANCISCO
STATE: CA
ZIP: 94158
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: IMPEL NEUROPHARMA INC
CENTRAL INDEX KEY: 0001445499
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 263058238
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 201 ELLIOTT AVE. W
STREET 2: SUITE 260
CITY: SEATTLE
STATE: WA
ZIP: 98119
BUSINESS PHONE: 206-568-1466
MAIL ADDRESS:
STREET 1: 201 ELLIOTT AVE. W
STREET 2: SUITE 260
CITY: SEATTLE
STATE: WA
ZIP: 98119
4
1
form4.xml
X0306
4
2021-04-27
0001445499
IMPEL NEUROPHARMA INC
IMPL
0001634632
venBio Global Strategic Fund II L.P.
1700 OWENS STREET
SUITE 595
SAN FRANCISCO
CA
94158
true
0001729409
venBio Global Strategic GP II, L.P.
1700 OWENS STREET
SUITE 595
SAN FRANCISCO
CA
94158
true
0001729408
venBio Global Strategic GP II, Ltd.
1700 OWENS STREET
SUITE 595
SAN FRANCISCO
CA
94158
true
0001278411
GOODMAN COREY S
1700 OWENS STREET
SUITE 595
SAN FRANCISCO
CA
94158
true
0001329161
Adelman Robert J
1700 OWENS STREET
SUITE 595
SAN FRANCISCO
CA
94158
true
Common Stock
2021-04-27
4
C
0
2309791
A
2309791
D
Common Stock
2021-04-27
4
P
0
450000
15
A
2759791
D
Series D Redeemable Convertible Preferred Stock
2021-04-27
4
C
0
5876034
0
D
Common Stock
358878
0
D
Series C-3 Redeemable Convertible Preferred Stock
2021-04-27
4
C
0
8201930
0
D
Common Stock
500932
0
D
Series C-2 Redeemable Convertible Preferred Stock
2021-04-27
4
C
0
8845942
0
D
Common Stock
540265
0
D
Series C-1 Redeemable Convertible Preferred Stock
2021-04-27
4
C
0
13233885
0
D
Common Stock
808259
0
D
5% Convertible Note due 2021
2021-04-27
4
C
0
1359799.28
0
D
2021-12-31
Common Stock
101457
0
D
These shares of the issuer's Series D redeemable convertible preferred stock automatically converted on a 16.37332-for-one basis into the number of shares of the issuer's common stock shown in Column 7 immediately upon closing of the issuer's initial public offering ("IPO"), and had no expiration date.
These shares of the issuer's Series C-3 redeemable convertible preferred stock automatically converted on a 16.37332-for-one basis into the number of shares of the issuer's common stock shown in Column 7 immediately upon closing of the issuer's IPO, and had no expiration date.
These shares of the issuer's Series C-2 redeemable convertible preferred stock automatically converted on a 16.37332-for-one basis into the number of shares of the issuer's common stock shown in Column 7 immediately upon closing of the issuer's IPO, and had no expiration date.
These shares of the issuer's Series C-1 redeemable convertible preferred stock automatically converted on a 16.37332-for-one basis into the number of shares of the issuer's common stock shown in Column 7 immediately upon closing of the issuer's IPO, and had no expiration date.
This convertible promissory note was issued by the issuer in March 2021 and the outstanding principal and accrued interest automatically converted into the number of shares of the issuer's common stock shown in Column 7 upon the closing of the issuer's IPO at $13.50 per share (90% of the IPO price).
The shares are held by venBio Global Strategic Fund II, L.P. venBio Global Strategic GP II, LP is the sole general partner of venBio Global Strategic Fund II, LP and venBio Global Strategic GP II, Ltd. is the sole general partner of venBio Global Strategic GP II, L.P. Each of Corey Goodman and Robert Adelman is a director of venBio Global Strategic GP II, Ltd. Each of venBio Global Strategic GP II, LP, venBio Global Strategic GP II, Ltd, Dr. Goodman and Dr. Adelman disclaims beneficial ownership of such securities, except to the extent of its/his indirect pecuniary interest therein.
venBio Global Strategic Fund II, L.P., by: venBio Global Strategic GP II, L.P., its general partner, by: venBio Global Strategic GP II, Ltd., its general partner, by: /s/ David Pezeshki, as attorney-in-fact
2021-04-29
venBio Global Strategic GP II, L.P., by: venBio Global Strategic GP II, Ltd., its general partner, by: /s/ David Pezeshki as attorney-in-fact
2021-04-29
venBio Global Strategic GP II, Ltd., by: /s/ David Pezeshki, as attorney-in-fact
2021-04-29
Corey Goodman, by: /s/ David Pezeshki, as attorney-in-fact
2021-04-29
Robert Adelman, by: /s/ David Pezeshki, as attorney-in-fact
2021-04-29